Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer.


Journal

Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042

Informations de publication

Date de publication:
02 2019
Historique:
received: 30 04 2018
revised: 02 08 2018
accepted: 11 10 2018
pubmed: 20 10 2018
medline: 28 1 2020
entrez: 19 10 2018
Statut: ppublish

Résumé

Resistance to standard therapy remains a major challenge in the treatment of pancreatic ductal adenocarcinoma (PDA). Although anti-VEGF therapy delays PDA progression, therapy-induced hypoxia results in a less differentiated mesenchymal-like tumor cell phenotype, which reinforces the need for effective companion therapies. COX-2 inhibition has been shown to promote tumor cell differentiation and improve standard therapy response in PDA. Here, we evaluate the efficacy of COX-2 inhibition and VEGF blockade in preclinical models of PDA.

Identifiants

pubmed: 30333153
pii: 1541-7786.MCR-18-0427
doi: 10.1158/1541-7786.MCR-18-0427
pmc: PMC6359969
mid: NIHMS1509935
doi:

Substances chimiques

Cyclooxygenase 2 Inhibitors 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

348-355

Subventions

Organisme : NCI NIH HHS
ID : U54 CA210181
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA196033
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA136515
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA192381
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA138464
Pays : United States

Informations de copyright

©2018 American Association for Cancer Research.

Références

Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Cancer. 2016 Apr;16(4):201-18
pubmed: 27009393
J Clin Invest. 2013 Aug;123(8):3190-200
pubmed: 23908119
Cancer Lett. 2017 Oct 28;407:57-65
pubmed: 28826722
Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11
pubmed: 15179620
Clin Cancer Res. 2003 Mar;9(3):961-8
pubmed: 12631593
Annu Rev Immunol. 2006;24:99-146
pubmed: 16551245
J Clin Oncol. 2009 May 1;27(13):2231-7
pubmed: 19307500
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6
pubmed: 23045683
Cell Rep. 2016 Sep 27;17(1):233-248
pubmed: 27681434
J Gastroenterol Hepatol. 2014 Nov;29(11):1932-42
pubmed: 24909904
Nat Rev Immunol. 2010 Aug;10(8):554-67
pubmed: 20616810
J Clin Oncol. 2010 Aug 1;28(22):3617-22
pubmed: 20606091
Annu Rev Pathol. 2007;2:251-75
pubmed: 18039100
Gastroenterology. 1994 Oct;107(4):1183-8
pubmed: 7926468
Curr Drug Targets. 2011 Jun;12(7):1082-93
pubmed: 21443470
Cancer Lett. 2014 Feb 28;343(2):147-55
pubmed: 24141189
Int J Cell Biol. 2010;2010:215158
pubmed: 20339581
Sci Transl Med. 2014 Jun 25;6(242):242ra84
pubmed: 24964992
Clin Cancer Res. 2012 Sep 15;18(18):5031-42
pubmed: 22829202
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Cancer Res. 2014 Feb 15;74(4):1032-44
pubmed: 24346431
CA Cancer J Clin. 2013 Sep;63(5):318-48
pubmed: 23856911
J Clin Invest. 2000 Jun;105(11):1589-94
pubmed: 10841517
Pharmacol Rep. 2010 Mar-Apr;62(2):233-44
pubmed: 20508278
Science. 2005 Jan 7;307(5706):58-62
pubmed: 15637262
Cancer Res. 2017 Aug 1;77(15):3982-3989
pubmed: 28428275
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Oncotarget. 2015 Mar 20;6(8):6341-58
pubmed: 25849942
Cancer Cell. 2009 Mar 3;15(3):220-31
pubmed: 19249680
Nat Med. 2015 Apr;21(4):327-34
pubmed: 25799228
Nat Med. 1999 Dec;5(12):1418-23
pubmed: 10581086
Cancer Cell. 2009 Mar 3;15(3):195-206
pubmed: 19249678
J Clin Oncol. 2013 Mar 20;31(9):1219-30
pubmed: 23401453
Cancer Lett. 2016 Oct 10;381(1):244-51
pubmed: 26723878
Crit Rev Oncol Hematol. 2007 Jan;61(1):52-69
pubmed: 16945549
Cancer Metastasis Rev. 2000;19(1-2):19-27
pubmed: 11191059
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Carcinogenesis. 2012 Sep;33(9):1639-46
pubmed: 22678114
Invest Ophthalmol Vis Sci. 1998 Mar;39(3):581-91
pubmed: 9501870
N Engl J Med. 2008 May 8;358(19):2039-49
pubmed: 18463380
J Gastroenterol Hepatol. 2012 Mar;27(3):566-78
pubmed: 22097969
PLoS One. 2010 Aug 06;5(8):e12031
pubmed: 20700512
Genes Dev. 2003 Dec 15;17(24):3112-26
pubmed: 14681207
Nat Rev Cancer. 2010 Mar;10(3):181-93
pubmed: 20168319
Cancer Res. 2012 Jul 1;72(13):3125-30
pubmed: 22721837
Nat Rev Cancer. 2013 Dec;13(12):871-82
pubmed: 24263190
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Nature. 2015 Sep 10;525(7568):256-60
pubmed: 26331542

Auteurs

Yuqing Zhang (Y)

Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.

Amanda Kirane (A)

Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.
Division of Surgical Oncology, Department of Surgery, UC Davis Medical Center, Sacramento, California.

Huocong Huang (H)

Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.

Noah B Sorrelle (NB)

Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.

Francis J Burrows (FJ)

Kura Oncology, Inc., La Jolla, California.

Michael T Dellinger (MT)

Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.

Rolf A Brekken (RA)

Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas. rolf.brekken@utsouthwestern.edu.
Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH